Chimeric Toxin Delivery System for Neural Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current toxin-based delivery systems lack specificity and efficiency in targeting neural cells, particularly for therapeutic and diagnostic agents, due to non-specific binding and translocation mechanisms of Clostridium botulinum C2 toxin.
Innovation Solution
Development of chimeric toxin-based delivery compositions that incorporate a target cell binding unit, a pore-forming unit, and a payload unit, where the binding unit is derived from Clostridium botulinum neurotoxin C1 and the pore-forming unit is modified from Clostridium botulinum toxin C2, enabling specific delivery to neural cells by forming pores for payload translocation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If Clostridium botulinum C2 toxin is used as a delivery system, then payload translocation capability is provided, but cell targeting specificity is insufficient
Solution Approach 1:
The toxin is divided into separate functional domains: a binding domain (from C1 neurotoxin) for specific neural cell targeting, a translocation domain (from C2 toxin) for payload delivery, and a payload domain for the therapeutic agent. This segmentation allows each domain to be optimized for its specific function while working together as an integrated delivery system.
Solution Approach 2:
The patent merges the binding domain of C1 neurotoxin with the translocation domain of C2 toxin to create a chimeric toxin. This combination provides both specific neural cell targeting (from C1) and efficient payload translocation (from C2), resolving the contradiction between specificity and delivery efficiency.
2Adaptability or versatility
If native C2 toxin binding domain is used, then binding capability is provided, but neural cell specificity is lost
Solution Approach 1:
The binding domain is specifically engineered to recognize and bind to ganglioside GT1b on neural cell surfaces, providing local specificity to neural cells. This localized binding capability ensures that the toxin delivers its payload specifically to neural cells rather than other cell types.
Solution Approach 2:
Ganglioside GT1b serves as an intermediary receptor on the neural cell surface that mediates binding between the toxin's binding domain and the target cell. This intermediary mechanism enables specific neural cell targeting without requiring direct integration of complex targeting mechanisms into the toxin structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered system achieves targeted delivery of therapeutic and diagnostic agents to neural cells, enhancing specificity and efficiency while maintaining the mechanism of activation and translocation of the native C2 toxin, as demonstrated by increased cell rounding and intracellular payload delivery in enriched cell populations.
Implementation Method 1
a pore-forming unit, wherein the pore-forming unit forms pores in a membrane of the target cell
Implementation Method 2
translocate material (payloads) across the lipid bilayer into the cytosol of the targeted cell
Data Source
AI summary
An engineered payload-delivery system includes a target cell binding unit, covalently bound to a pore forming unit, and a payload portion adapted with a region capable of non-covalently binding to the pore forming unit. The pore forming unit is derived from a particular sub-serotype of Clostridium toxin, while the payload region is derived from a different sub-serotype of Clostridium toxin. The disclosed chimeric protein-based composition is capable of specifically delivering payload to neural cells.